No Data
No Data
Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Shanghai Mengke Pharmaceutical Co., Ltd.
Meinuo Pharmaceutical (688373.SH) released its first half financial performance, with a net loss of 0.201 billion yuan.
Mengke Pharmaceutical (688373.SH) released its semi-annual report for 2024, during which period the company achieved revenue...
Mingke Pharmaceuticals (688373.SH): a net loss of 201 million yuan in the first half of the year.
Gelonghui August 28th | Meike Pharma (688373.SH) released its 2024 interim report, with revenue of 60.738 million yuan, a year-on-year increase of 44.24%; net income attributable to the company's shareholders amounted to -0.201 billion yuan.
Mengke Pharmaceutical (688373.SH): intends to continue using temporarily idle raised funds of no more than 0.5 billion yuan for cash management.
On August 6th, Gelonghui reported that Mengke Pharmaceuticals (688373.SH) intends to continue using temporarily idle raised funds not exceeding RMB 0.5 billion (including principal) for cash management, with a single maximum term not exceeding 12 months, and valid within 12 months from the date of approval by the company's board of directors. Within the above-mentioned amount and validity period, the funds can be rolled over and used.
Mengke Pharmaceuticals showcased innovative antibiotic research results at the Seventh World Bronchiectasis Conference.
At the 7th World Bronchiectasis Conference, Minkang Pharmaceuticals showcased the latest research progress of its pipeline products MRX-8 and MRX-5. Three important research results further support the potential of MRX-8 and MRX-5 in treating non-tuberculosis mycobacterial lung disease and Pseudomonas aeruginosa infection. Dundee, Scotland, July 17, 2024 /PRNewswire/ - Shanghai Minkang Pharmaceutical Co., Ltd. ("Minkang Pharmaceuticals", 688373.SH) held at the 7th World Bronchiectasis Conference from July 4 to July 6, 2024 in Dundee, Scotland.
No Data